Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

Prior treatment

• History of a major cardiovascular event within 12 months prior to screening
• Severe or active infectious disease requiring treatment with antibiotics or antivirals within 4 weeks prior to randomization, or expected to require such treatment during the study period
• Clinically significant gastrointestinal disorders within 3 months prior to screening, or conditions that may lead to malabsorption
• Treatment with any disease-modifying therapy for Alzheimer's disease within 1 year prior to screening
• Initiation or dosage/regimen changes of symptomatic treatments for dementia within 12 weeks prior to screening
• Chronic use of medications acting on the CNS or those that may affect cognitive function within 8 weeks prior to screening
• Regular use of medications that may alter the gut microbiota within 4 weeks prior to screening

Other illness

• Subjects with clinically significant diseases other than Alzheimer's disease that may confound cognitive assessment
  • History of central nervous system (CNS) diseases
  • Active central nervous system (CNS) infection capable of affecting cognitive function, or a history of infection resulting in neurological sequelae
  • Structural brain abnormalities identified on screening MRI that could account for cognitive impairment
  • Abnormal thyroid function identified at screening
  • Vitamin B12 deficiency identified at screening
• History of seizure disorder or epilepsy
• History of psychiatric disorders, including schizophrenia, bipolar disorder, or clinically significant major depressive disorder, with current active symptoms
• History of malignancy diagnosed or recurrent within 5 years prior to screening
• Cardiovascular disease requiring the administration of anticoagulants

Other

• History or suspicion of alcohol or substance abuse/dependence

• Male and female adults aged ≥55 and ≤85 years at the time of written consent
• Subjects with a Korean Mini-Mental State Examination (K-MMSE) score of 20 to 28
• Have a global Clinical Dementia Rating (CDR) score of 0.5 to 1 and a CDR Memory Box score of 0.5 or greater
• Subjects who test positive for amyloid on Positron Emission Tomography (PET)